Skip to main content

Table 4 The effect of charged residue-to-alanine replacement on neutralization capacity of ITM4 plasma, CrossR1 plasma and Mab 4E10

From: Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies

VIRUS

COT6.15

MAB 4E10

ITM_01

ITM4_07

CROSSR1

AA

MUTATION

IC50a

IC50b

IC50c

IC50d

 

WT

1,11

603

3544

249

K

667A

0,43

556

>4860

367

N

668A

4,63

117

472

50

L

669A

0,15

929

>4860

528

W

670A

0,93

445

>4860

163

S

671A

0,23

644

>4860

211

W

672A

>25

241

4189

115

F

673A

>25

70

1177

39

D

674A

4,43

63

516

29

I

675A

0,15

333

>4860

193

T

676A

>25

188

2069

61

K

677A

0,38

640

4285

180

W

678A

0,22

801

>4860

391

L

679A

0,49

317

>4860

398

W

680A

4,00

479

>4860

360

  1. AA: amino acids in the 4E10 region of the COT6.15 virus
  2. Alanine-replacements inducing a 3-fold or higher decrease in sensitivity are indicated in grey.
  3. aAntibody concentration (μg/ml) causing 50% reduction of relative light units compared to the virus control.
  4. b Plasma dilution causing 50% reduction of relative light units compared to the virus control.